Protocol Ledger

NCT06970743 · Phase III · ACTIVE NOT RECRUITING

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhib

Interventional Phase III clinical trial protocol NCT06970743 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-29 Enrollment: 153 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06970743
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)153 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06970743
Protocol FieldVerified Registry Value
NCT IdentifierNCT06970743
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment153 participants (ACTUAL)
Registered Start Date2025-05-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI